BAB V SIMPULAN DAN SARAN
5.2. Saran
Hasil penelitian ini dapat dijadikan rekomendasi standar operasional mengenai pola penetesan, regimen, dan konsentrasi agen sikloplegik untuk anak dengan kelainan refraksi di Unit Pediatrik Oftalmologi PMN RS Mata Cicendo. Penelitian serupa juga dapat direncanakan dengan melibatkan subjek dengan usia lebih muda atau status kelainan refraksi yang lebih beragam, terutama dengan hipermetropia tinggi dan strabismus akomodatif. Penelitian lanjutan dapat dilakukan untuk menilai efektivitas regimen kombinasi obat apabila diracik sebagai satu sediaan.
74
DAFTAR PUSTAKA
1. World Health Organization. World report on vision. Switzerland; 2019.
2. Dhanesha U, Polack S, Bastawrous A, Banks LM. Prevalence and causes of visual impairment among schoolchildren in Mekelle, Ethiopia. Cogent Med.
2018;5:1554832.
3. Harrington SC, Stack J, Saunders K, O’Dwyer V. Refractive error and visual impairment in Ireland schoolchildren. Br J Ophthalmol. 2019;103(8):1112–8.
4. Halim A, Suganda R, Sirait NS, Memed KF, Syumarti, Rini M, et al. Prevalence and associated factors of uncorrected refractive errors among school children in suburban areas in Bandung, Indonesia. Cogent Med. 2020;7(1):1737354.
5. Mahayana IT, Indrawati SG, Pawiroranu S. The prevalence of uncorrected refractive error in urban, suburban, exurban and rural primary school children in Indonesian population. Int J Ophthalmol. 2017;10(11):1771–6.
6. Nikmah ST, Rifada RM, Santoso PTR. Refractive errors in state junior high school students in Bandung. Althea Med J. 2016;3(4):545–8.
7. Sherman AE, Shaw MM, Ralay-Ranaivo H, Rahmani B. Tropicamide has limited clinical effect on cycloplegia and mydriasis when combined with cyclopentolate and phenylephrine. J AAPOS. 2019;2.e1-30.e5.
8. Laojaroenwanit S, Layanun V, Praneeprachachon P, Pukrushpan P. Time of maximum cycloplegia after instillation of cyclopentolate 1% in children with brown irises. Clin Ophthalmol. 2016;10:897–902.
9. Kyei S, Nketsiah AA, Asiedu K, Awuah A, Owusu-Ansah A. Onset and duration of cycloplegic action of 1% cyclopentolate – 1% tropicamide combination. Afr Health Sci. 2017;17(3):923–32.
10. Yazdani N, Sadeghi R, Momeni-Moghaddam H, Zarifmahmoudi L, Ehsaei A.
Comparison of cyclopentolate versus tropicamide cycloplegia: A systematic review and meta-analysis. J Optom. 2018;11:135–43.
11. Yoo SG, Cho MJ, Kim US, Baek S-H. Cycloplegic refraction in hyperopic children: Effectiveness of a 0.5% tropicamide and 0.5% phenylephrine addition to 1% cyclopentolate regimen. Korean J Ophthalmol. 2017;31(3):249.
12. Pi LH, Zhao JL, Liu Q, Chen L, Fang J, Ke N, et al. Comparison of cycloplegic retinoscopy using cyclopentolate or tropicamide eye drops in an epidemiologic study of pediatric refraction among 1907 school-aged children. Sci Res Essays.
2011;6(3):635–40.
13. Bagheri A, Givrad S, Yazdani S, Mohebbi MR. Optimal dosage of cyclopentolate 1% for complete cycloplegia: A randomized clinical trial. Eur J Ophthalmol. 2007;17(3):294–300.
14. American Academy of Ophthalmology. Pediatric Eye Evaluations Preferred Practice Pattern®. Elsevier Inc.; 2017. p.185–227
15. Fan DSP, Rao SK, Ng JSK, Yu CBO, Lam DSC. Comparative study on the safety and efficacy of different cycloplegic agents in children with darkly pigmented irides. Clin Exp Ophthalmol. 2004;32:462–7.
16. Minderhout HM, Joosse M V, Grootendorst DC, Schalij-Delfos NE. A randomized clinical trial using atropine, cyclopentolate, and tropicamide to compare refractive outcome in hypermetropic children with a dark iris; skin pigmentation and crying as significant factors for hypermetropic outcome.
Strabismus. 2019;27(3):127–38.
17. Frazier M, Jaanus SD. Cycloplegics. In: Bartlett JD, Jaanus SD, editors. Clinical ocular pharmacology. 5th ed. Missouri, USA: Elsevier; 2008. p. 124–38.
18. Gupra SK. Mydriatics and cycloplegics. In: Gupra SK, Agarwal R, Srivastava S, editors. Textbook on clinical ocular pharmacology and therapeutics. New Delhi, India: Jaypee Brothers Medical Publishers; 2014. p. 87–95
19. Chng O, Jones N, Kian K, Ming K, Kee S. Is tropicamide a more effective cycloplegic than cyclopentolate in children with dark irides? Aust Orthopt J.
2005;38:2–4.
20. Llewellyn S, Khandelwal P, Glaze S, Thomas P, Dahlmann-Noor A. Time to drop the phenylephrine from the paediatric cycloplegia protocol: informing practice through audit. Eye. 2019;33:337–8.
21. Patel AJ, Simon JW, Hodgetts DJ. Cycloplegic and mydriatic agents for routine ophthalmologic examination: A survey of pediatric ophthalmologists. J AAPOS. 2004;8:274–7.
22. Wren VQ, Krumholz DM, Portello JK, Rosenfield M, Rosenbaum JD. The Effectiveness of cycloplegia and pupillary dilation with cyclopentolate, tropicamide, and phenylephrine in a single combination solution. Optom Vis Sci. 2000;77:129.
23. Sujuan JL, Handa S, Perera C, Chia A. The psychological impact of eyedrops administration in children. J AAPOS. 2015;19:338–43.
24. Esteve-Taboada JJ, Del Águila-Carrasco AJ, Bernal-Molina P, Ferrer-Blasco T, López-Gil N, Montés-Micó R. Effect of phenylephrine on the accommodative system. J Ophthalmol. 2016;7968918.
25. Anderson HA, Bertrand KC, Manny RE, Hu YS, Fern KD. A Comparison of two drug combinations for dilating dark irides. Optom Vis Sci. 2010;87(2):120–
4.
26. Skalicky SE. Ocular and visual physiology. Sydney, Australia: Springer; 2016.
p.58–60, 67–69, 85–96.
27. Remington LA. Clinical anatomy and physiology of the visual system. 3rd ed.
Vol. 53. Elsevier; 2012. p.1689–1699.
28. Szczepanowska-Nowak W, HachoŁ A, Kasprzak H. System for measurement of the consensual pupil light reflex. Opt Appl. 2004;34(4):619–34.
29. Netter FH. Atlas of human anatomy. 6th ed. Philadelphia, USA: Saunders Elsevier; 2014.
30. Hall CA, Chilcott RP. Eyeing up the future of the pupillary light reflex in neurodiagnostics. Diagnostics. 2018;8(19).
31. Netter FH. Netter’s cranial nerve collection. Philadelphia, USA: Elsevier; 2016.
32. Park JH, Lee YC, Lee SY. The comparison of mydriatic effect between two drugs of different mechanism. Korean J Ophthalmol. 2009;23(1):40–2.
33. Ciuffreda KJ. Accommodation, the pupil, and presbyopia. In: Benjamin WJ, editor. Borish’s clinical refraction. 2nd ed. Missouri, USA: Elsevier; 2006. p.
93–144.
34. Rosenfield M. Development of accommodation in human infants. In: Duckman RH, editor. Visual development, diagnosis, and treatment of the pediatric patients. Philadelphia, USA: Lippincott Williams & Wilkins; 2006. p. 110–23.
35. Maheshwari R, Sukul RR, Gupta Y, Gupta M, Phougat A, Dey M, et al.
Accommodation: its relation to refractive errors, amblyopia and biometric parameters. Nepal J Ophthalmol. 2011;3(2):146–50.
36. Od MBT, Shallo-hoffmann J. A Comparison of three clinical tests of accommodation amplitude to Hofstetter’s Norms to guide diagnosis and treatment. Optom Vis Dev. 2012;43(4):180–90.
37. American Academy of Ophthalmology. Clinical optics. San Fransisco, USA;
2019.
38. Hashemi H, Pakbin M, Ali B, Yekta A, Ostadimoghaddam H, Asharlous A, et al. Near points of convergence and accommodation in a population of university students in Iran. J Ophthalmic Vis Res. 2019;14(3):306–14.
39. Chen Y, Drobe B, Zhang C, Singh N, Spiegel DP, Chen H, et al.
Accommodation is unrelated to myopia progression in Chinese myopic children. Sci Rep. 2020;10(1):1–8.
40. Schultz KE, Sinnott LT, Mutti DO, Bailey MD. Ciliary body thickness in children. Optom Vis Sci. 2009;86(6):677–84.
41. Mutti DO, Jones LA, Moeschberger ML, Zadnik K. AC/A ratio, age, and refractive error in children. Investig Ophthalmol Vis Sci. 2000;41(9):2469–78.
42. Toor S, Horwood A, Riddell P. The effect of asymmetrical accommodation on anisometropic amblyopia treatment outcomes. J AAPOS. 2019;23(4):203.e1-203.e5.
43. Toor S, Horwood AM, Riddell P. Asymmetrical accommodation in hyperopic anisometropic amblyopia. Br J Ophthalmol. 2018;102(6):772–8.
44. Marran L, Schor CM. Binocular accommodation. In: Franzen O, Stark L, Richter H, editors. Accommodation and vergence mechanisms in the visual system. Springer; 2000. p. 245–56.
45. Manh V, Chen AM, Tarczy-Hornoch K, Cotter SA, Candy TR. Accommodative performance of children with unilateral amblyopia. Investig Ophthalmol Vis Sci. 2015;56:1193–207.
46. Minderhout HM, Joosse M V, Grootendorst DC, Schalij-Delfos NE. Adverse reactions following routine anticholinergic eye drops in a paediatric population:
An observational cohort study. BMJ Open. 2015;5:e008798.
47. Bourne RRA, Flaxman SR, Braithwaite T, Cicinelli M V., Das A, Jonas JB, et al. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Heal. 2017;5(9):e888–97.
48. Portello JK. Mydriatics and mydriolytics. In: Bartlett JD, Jaanus SD, editors.
Clinical ocular pharmacology. 5th ed. Missouri, USA: Elsevier; 2008. p. 112–
23.
49. Tanner V, Casswell AG. A comparative study of the efficacy of 2.5%
phenylephrine and 10% phenylephrine in pre-operative mydriasis for routine cataract surgery. Eye. 1996 Jan;10(1):95–8.
50. Lim J, Chia A, Saffari SE, Handa S. Factors affecting pupil reactivity after cycloplegia in Asian children. Asia-Pacific J Ophthalmol. 2019;8(4):304–7.
51. Suwan-Apichon O, Ratanapakorn T, Panjaphongse R, Sinawat S, Sanguansak T, Yospaiboon Y. 2.5% and 10% phenylephrine for mydriasis in diabetic patients with darkly pigmented irides. J Med Assoc Thail. 2010 Apr;93(4):467–
73.
52. Kleinstein RN, Mutti DO, Manny RE, Shin JA, Zadnik K. Cycloplegia in African-American children. Vol. 76, Optometry and Vision Science. 1999. p.
102–7.
53. Zetterström C. A cross‐over study of the cycloplegic effects of a single topical application of cyclopentolate‐phenylephrine and routine atropinisation for 3.5 days. Acta Ophthalmol. 1985;63(5):525–9.
54. Fredrick DR. Myopia. BMJ. 2002;324:1196–9.
55. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Edisi 3. Jakarta: Salemba Medika; 2010.
56. Madiyono B, Mz SM, Sastroasmoro S, Budiman I, Purwanto SH. Perkiraan besar sampel. Dalam: Sastroasmoro S, Ismael S, editor. Dasar-dasar metodologi penelitian klinis. Edisi 3. Jakarta: CV. Sagung Seto; 2008. h. 302–31.
57. Harun SR, Putra ST, Chair I, Sastroasmoro S. Uji klinis. Dalam: Sastroasmoro S, Ismael S, editor. Dasar-dasar metodologi penelitian klinis. Edisi 3. Jakarta:
CV. Sagung Seto; 2008. h. 166–92.
58. Dahlan MS. Statistik untuk kedokteran dan kesehatan. Edisi 3. Jakarta: Salemba Medika; 2011.
59. Ebri A, Kuper H, Wedner S. Cost-effectiveness of cycloplegic agents: Results of a randomized controlled trial in Nigerian children. Investig Ophthalmol Vis Sci. 2007;48(3):1025–31.
60. Lin LLK, Shih YF, Hsiao CH, Su TC, Chen CJ, Hung PT. The cycloplegic effects of cyclopentolate and tropicamide on myopic children. J Ocul Pharmacol Ther. 1998;14(4):331–5.
78
DAFTAR LAMPIRAN
Lampiran 1 Persetujuan Etik ...79 Lampiran 2 Lembar Informasi dan Persetujuan (Informed Consent) ...80 Lampiran 3 Data Hasil Penelitian ...84 Lampiran 4 Analisis Statistik...90 Lampiran 5 Daftar Riwayat Hidup ... 102
Lampiran 1
Lampiran 2
Lampiran 4
ANALISIS STATISTIK
Uji Homogenitas Karakteristik Subjek Penelitian antara Kelompok SFT Dan SF
Jenis Kelamin
Usia
Kategori Usia
Status Kelainan Refraksi
Kekuatan Refraksi dan Diameter Pupil
Independent Samples Test Levene's Test
for Equality of
Variances t-test for Equality of Means
F Sig. t df
Sig. (2-tailed)
Mean Difference
Std. Error Difference
95%
Confidence Interval of the
Difference Lower Upper DiameterPupil Equal
variances assumed
.156 .693 .068 106 .946 .0093 .1355 -.2593 .2778
Equal variances not assumed
.068 105.229 .946 .0093 .1355 -.2593 .2779
Tabel Kekuatan Refraksi dan Ukuran Diameter Pupil pada Menit ke-20, 30, 45, dan 60
Kelompok SFT
Statistics
Kekuatan Refraksi Menit 20
Kekuatan Refraksi Menit 30
Kekuatan Refraksi Menit 45
Kekuatan Refraksi Menit 60
Diameter Pupil Menit 20
Diameter Pupil Menit
30
Diameter Pupil Menit 45
Diameter Pupil Menit 60
N Valid 54 54 54 54 54 54 54 54
Missing 0 0 0 0 0 0 0 0
Mean -2.6204 -2.5463 -2.5185 -2.4769 6.869 7.967 8.461 8.650
Median -2.3750 -2.3750 -2.3750 -2.2500 6.950 8.150 8.600 8.750
Std. Deviation 2.24225 2.26388 2.20679 2.23779 .7684 .5474 .5360 .5333
Minimum -6.75 -7.00 -6.75 -7.00 4.9 6.6 7.0 7.1
Maximum 2.00 2.00 2.00 2.00 8.0 8.7 9.3 9.6
Kelompok SF
Statistics
Kekuatan Refraksi Menit 20
Kekuatan Refraksi Menit 30
Kekuatan Refraksi Menit 45
Kekuatan Refraksi Menit 60
Diameter Pupil Menit 20
Diameter Pupil Menit
30
Diameter Pupil Menit45
Diameter Pupil Menit60
N Valid 54 54 54 54 54 54 54 54
Missing 0 0 0 0 0 0 0 0
Mean -2.3102 -2.2917 -2.2083 -2.1852 6.613 7.237 7.980 8.372
Median -2.1250 -2.1250 -2.0000 -2.0000 6.650 7.300 8.000 8.400
Std. Deviation 2.25180 2.21527 2.24015 2.25559 .6898 .6634 .5427 .4672
Minimum -7.00 -7.00 -6.75 -6.50 4.8 5.9 6.9 7.1
Maximum 1.00 .75 1.00 1.00 8.0 8.4 9.1 9.2
Tabel Analisis Perbandingan Perubahan Kekuatan Refraksi dan Perubahan Ukuran Diameter Pupil antara Kelompok SFT Dan SF
Tests of Normality Kelompok
Kolmogorov-Smirnova Shapiro-Wilk Statistic df Sig. Statistic df Sig.
PerbedaanKekuatanRef 20
SFT .251 54 .000 .823 54 .000
SF .264 54 .000 .856 54 .000
PerbedaanKekuatanRef 30
SFT .260 54 .000 .852 54 .000
SF .227 54 .000 .879 54 .000
PerbedaanKekuatanRef 45
SFT .261 54 .000 .782 54 .000
SF .246 54 .000 .861 54 .000
PerbedaanKekuatanRef 60
SFT .222 54 .000 .816 54 .000
SF .212 54 .000 .820 54 .000
PerbedaanDiameterPupil 20
SFT .121 54 .048 .969 54 .166
SF .101 54 .200* .966 54 .133
PerbedaanDiameterPupil 30
SFT .088 54 .200* .979 54 .478
SF .096 54 .200* .976 54 .342
PerbedaanDiameterPupil 45
SFT .114 54 .078 .967 54 .135
SF .062 54 .200* .986 54 .786
PerbedaanDiameterPupil 60
SFT .113 54 .082 .961 54 .076
SF .070 54 .200* .992 54 .982
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Independent Samples Test Levene's Test
for Equality of
Variances t-test for Equality of Means
F Sig. t df
Sig. (2-tailed)
Mean Differe nce
Std.
Error Differe nce
95% Confidence Interval of the
Difference Lower Upper Perbedaan
Diameter Pupil30
Equal variances assumed
.694 .407 4.937 106 .000 .7204 .1459 .4311 1.0097
Equal variances not assumed
4.937 104.338 .000 .7204 .1459 .4310 1.0097
Perbedaan DiameterP upil45
Equal variances assumed
1.078 .302 3.061 106 .003 .4722 .1543 .1664 .7781
Equal variances not assumed
3.061 104.953 .003 .4722 .1543 .1663 .7781
Perbedaan Diameter Pupil60
Equal variances assumed
2.896 .092 1.725 106 .088 .2685 .1557 -.0402 .5772
Equal variances not assumed
1.725 102.762 .088 .2685 .1557 -.0403 .5773
Tabel Analisis Perbandingan Waktu Puncak Sikloplegik dan Waktu Puncak Midriasis antara Kelompok SFT dan SF
Tabel Analisis Perbandingan Perubahan Kekuatan Refraksi dan Perubahan Ukuran Diameter Pupil antara Kelompok SFT dan SF
pada Usia 6 – 12 Tahun
Test Statisticsa Perbedaan
Kekuatan Ref 20
Perbedaan Kekuatan
Ref 30
Perbedaan Kekuatan
Ref 45
Perbedaan Kekuatan
Ref 60
Perbedaan Diameter
Pupil 45
Perbedaan Diameter
Pupil 60
Mann-Whitney U 199.000 176.000 172.000 172.000 147.000 180.500
Wilcoxon W 409.000 386.000 382.000 382.000 357.000 390.500
Z -.028 -.658 -.770 -.775 -1.437 -.529
Asymp. Sig. (2-tailed) .978 .511 .441 .439 .151 .597
Exact Sig. [2*(1-tailed Sig.)] .989b .529b .461b .461b .157b .602b a. Grouping Variable: Kelompok
b. Not corrected for ties.
Independent Samples Test Levene's Test
for Equality of
Variances t-test for Equality of Means
F Sig. t df
Sig. (2-tailed)
Mean Difference
Std. Error Difference
95% Confidence Interval of the
Difference Lower Upper Perbedaan
Diameter Pupil20
Equal variances assumed
.100 .753 .200 38 .842 .0350 .1748 -.3190 .3890
Equal variances not assumed
.200 36.813 .842 .0350 .1748 -.3193 .3893
Perbedaan Diameter Pupil30
Equal variances assumed
1.974 .168 2.488 38 .017 .5700 .2291 .1062 1.0338
Equal variances not assumed
2.488 35.540 .018 .5700 .2291 .1051 1.0349
Tabel Analisis Perbandingan Perubahan Kekuatan Refraksi dan Perubahan Ukuran Diameter Pupil antara Kelompok SFT dan SF
pada Usia 13 – 18 Tahun
Independent Samples Test Levene's Test
for Equality of
Variances t-test for Equality of Means
F Sig. t df
Sig. (2-tailed)
Mean Difference
Std. Error Difference
95% Confidence Interval of the
Difference Lower Upper Perbedaan
Diameter Pupil20
Equal variances assumed
.110 .741 2.199 66 .031 .3706 .1685 .0341 .7071
Equal variances not assumed
2.199 65.634 .031 .3706 .1685 .0341 .7071
Perbedaan Diameter Pupil30
Equal variances assumed
.017 .895 4.261 66 .000 .8088 .1898 .4298 1.1878
Equal variances not assumed
4.261 65.853 .000 .8088 .1898 .4298 1.1879
Perbedaan Diameter Pupil45
Equal variances assumed
.006 .936 2.489 66 .015 .5000 .2009 .0989 .9011
Equal variances not assumed
2.489 65.999 .015 .5000 .2009 .0989 .9011
Perbedaan Diameter Pupil60
Equal variances assumed
.709 .403 1.366 66 .177 .2706 .1981 -.1249 .6661
Equal variances not assumed
1.366 65.080 .177 .2706 .1981 -.1250 .6662
Lampiran 5
DAFTAR RIWAYAT HIDUP
Nama : Fany Gunawan
Tempat/Tanggal Lahir : Sukabumi, 25 Juli 1990
Alamat : Kopo Permai 1 Blok O no. 19, Bandung 40227 The Gardens Blok A1 no 17, Cirebon
Nama Orang Tua : Chandra Gunawan, B.Sc Tjatjan Suharti
Nama Suami : Herman, dr., SpM Nama Anak : Albert Pradipta Chandra
Riwayat Pendidikan Formal
1. SD Mardi Yuana, Cibadak, Sukabumi (1995 – 2000) 2. SD Maria Bintang Laut, Bandung (2000 – 2001) 3. SMP Waringin, Bandung (2001 – 2004)
4. SMA Trinitas, Bandung (2004 – 2007)
5. Program Studi Sarjana Kedokteran, Fakultas Kedokteran Universitas Kristen Maranatha, Bandung (2007 – 2011)
6. Program Studi Profesi Dokter, Fakultas Kedokteran Universitas Kristen Maranatha, Bandung (2011 – 2012)
7. Program Pendidikan Dokter Spesialis 1 Ilmu Kesehatan Mata, Fakultas Kedokteran Universitas Padjadjaran, Bandung (2017 – 2021)
Riwayat Pekerjaan
1. Staf pengajar di Lembaga Bimbingan Belajar “Medicuss” Bandung (2013) 2. Dokter internship, RST Ciremai, Cirebon dan Puskesmas Kalijaga
(2013 – 2014)
3. Dokter umum, RS Kebonjati, Bandung (2014 – 2015)
4. Dokter umum, Klinik Pratama Luhur Medica Center, Bandung (2014 – 2015) 5. Dokter umum, PT. Delapan Empat Sakti, Ketapang, Bandung (2014)
6. Dokter umum, RS Immanuel, Bandung (2015)
7. Dokter umum, Klinik Mitra Medika, Dayeuhkolot, Bandung (2015) 8. Dokter PTT, RS Fatima, Kab. Ketapang, Kalimantan Barat (2015 – 2017)
Pengalaman Organisasi
1. Bendahara II Asian Medical Students’ Association (AMSA) Fakultas Kedokteran Universitas Kristen Maranatha (FK UKM) (2008 – 2009)
2. Anggota Divisi Konsumsi Musyawarah Nasional (Munas) XXIII AMSA, Bandung (2008)
3. Sekretaris I AMSA FK UKM (2009 – 2010)
4. Perwakilan Universitas Kristen Maranatha dalam Munas AMSA XXIV di Unika Atmajaya, Jakarta (2009)
5. Anggota Divisi Medis kegiatan Orientasi Mahasiswa Baru UKM (2009) 6. Panitia simposium “Continuing Professional Development I” di Hotel Horison,
Bandung (2009)
7. Sekretaris I Komisi Pemilihan Umum (KPU) SEMA FK UKM (2010)
8. Anggota Divisi Acara Cicendo International Ophthalmology Meeting, Bandung (2019)
Penelitian/Penulisan Karya Ilmiah
1. Efek Antidiare Infusa Kulit Buah Rambutan (Nephelium lappaceium L.) pada Mencit Swiss Webster Jantan (2010)
2. Kesadaran, Pengetahuan, Sikap, dan Perilaku tentang Glaukoma pada Kelompok Usia di Atas 50 tahun di Kecamatan Tempuran, Kabupaten Karawang, Provinsi Jawa Barat, Indonesia (2018)
3. Surgically Induced Necrotizing Scleritis setelah Eksisi Pterygium Metode Bare Sclera, dimuat dalam Oftalmologica Indonesiana 2020 vol. 46 no. 2 (Agustus
2020)
4. Perbandingan Efek Sikloplegik dan Midriasis antara Kombinasi Siklopentolat 1% dan Fenilefrin 2,5% Dengan dan Tanpa Tropikamid 1% pada Anak dengan Kelainan Refraksi (2021)
Presentasi Ilmiah
1. Surgically Induced Necrotizing Scleritis After Pterygium Excision with Bare Sclera Technique
Presentasi poster pada Pertemuan Ilmiah Tahunan (PIT) PERDAMI ke-44, Makassar (2019)